• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MBIO

MBIO

Mustang Bio, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.74

-0.02 (-2.64%)

Rating:C+

Company Profile

CEO

Manuel Litchman

IPO Date

2017-08-22

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.76

Prev. Close

$0.76

Day Low

$0.74

Day High

$0.80

52W Low

$0.53

52W High

$7.00

Market Cap

$0.01B

Volume

0.07M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

27.3%

Avg Negative

1.3%

Avg Neutral

71.3%

News Feed

Mustang Bio to Present at the Raymond James Human Health Innovation Conference

GlobeNewsWire·6/16/2021·↑ positive

MBIO Stock Price: Over 7% Increase Explanation

Pulse2·6/11/2021·↑ positive

Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial

Benzinga·6/11/2021·↑ positive

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

GlobeNewsWire·6/11/2021·↑ positive

5 Penny Stocks To Watch Right Now That Analysts Are Bullish On

PennyStocks·5/18/2021·↑ positive

BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients

Benzinga·5/18/2021·↑ positive

Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

GlobeNewsWire·5/14/2021·↑ positive

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

GlobeNewsWire·5/12/2021·↑ positive

Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

GlobeNewsWire·5/10/2021·↑ positive

Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

GlobeNewsWire·3/24/2021·↑ positive